Tevogen Inc. (TVGN) stock
Close on Nov 12, 2026Market cap $37.25MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $37.25M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$21.61M
- EPS, diluted
- -$6.98
- Free cash flow
- -$12.39M
- Book value per share
- -$2.32
- Diluted shares
- 4M
Trading
- Previous close
- $6.00
- Open
- $5.99
- Day's range
- $5.06 – $6.87
- Volume
- 19,768
- Average volume (20 days)
- 11,161
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.34
- 52-week range
- $3.64 – $24.91
- RSI (14 days)
- 41.5
- Volatility (1 year)
- 112.5%
- Relative volume
- 1.98×
- WACC
- 7.4%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | TVGN | S&P 500 | Difference | TVGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -14.4% | -2.7% | −11.7 pts | ||
| 3 months | -11.6% | -1.7% | −9.8 pts | ||
| Year to date | -65.4% | +11.9% | −77.3 pts | ||
| 1 year | -75.4% | +12.0% | −87.4 pts | ||
| 3 years | -99.0% | +78.2% | −177.1 pts | -78.1% | +21.2% |
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Tevogen filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Update
- Update
- Update
- Results
About Tevogen
Biological Products, (No Diagnostic Substances)
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and neurological disorders. Utilizing its proprietary ExacTcell technology, the company harnesses naturally occurring CD8+ cytotoxic T lymphocytes (killer T cells) to target multiple specific antigens without genetic engineering. Its leading clinical product candidate, TVGN 489, is being developed for the treatment and prevention of COVID-19 and Long COVID, particularly in high-risk elderly and immunocompromised patients. The company’s pipeline also includes investigational therapies targeting viral infections and oncology indications.
Company profile, executives and historyTevogen stock: common questions
What is Tevogen's stock price?
TVGN closed at $5.72 on Nov 12, 2026, down 4.67% on the day. Over the past 52 weeks it traded between $3.64 and $24.91.
What is Tevogen's market cap?
Tevogen was worth $37.25M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is TVGN's P/E ratio?
Tevogen lost money over the twelve months to Jun 30, 2026 (diluted EPS -$6.98), so it has no meaningful P/E ratio.
Does Tevogen pay a dividend?
No. Tevogen has not paid a cash dividend over the last twelve months.
How has TVGN stock performed over the past year?
Including dividends, TVGN returned -75.4% over the past year, against +12.0% for the S&P 500.
Who are Tevogen's competitors?
Companies most similar to Tevogen by business, industry and size include INAB, IPSC, ALLO, TCRX, INKT.
See a number that looks wrong?